验证数据展示
经过测试的应用
| Positive FC detected in | human PBMCs |
推荐稀释比
| 应用 | 推荐稀释比 |
|---|---|
| Flow Cytometry (FC) | FC : 0.2 ug per 10^6 cells in 100 μl suspension |
| This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
产品信息
65198-1-Ig targets CD21 in FC applications and shows reactivity with human samples.
| 经测试应用 | FC Application Description |
| 经测试反应性 | human |
| 免疫原 |
N/A 种属同源性预测 |
| 宿主/亚型 | Mouse / IgG1, kappa |
| 抗体类别 | Monoclonal |
| 产品类型 | Antibody |
| 全称 | complement component (3d/Epstein Barr virus) receptor 2 |
| 别名 | BU32, C3DR, Complement C3d receptor, Complement receptor type 2, CR2 |
| 计算分子量 | 1092 aa, 119 kDa |
| GenBank蛋白编号 | BC136394 |
| 基因名称 | CD21 |
| Gene ID (NCBI) | 1380 |
| ENSEMBL Gene ID | ENSG00000117322 |
| RRID | AB_2918468 |
| 偶联类型 | Unconjugated |
| 形式 | Liquid |
| 纯化方式 | Protein A purification |
| UNIPROT ID | P20023 |
| 储存缓冲液 | PBS with 0.09% sodium azide, pH 7.3. |
| 储存条件 | Store at 2-8°C. Stable for one year after shipment. |
背景介绍
CD21, also known as complement receptor type 2 (CR2), complement C3d receptor, and Epstein-Barr virus receptor, is a transmembrane protein that contains a small cytoplasmic domain, a transmembrane region and an extracellular domain consisting of 15 tandem short consensus repeat sequences (PMID: 6230668; 2551147). It is expressed on B cells, follicular dendritic cells, thymocytes and a subset of peripheral T cells (PMID: 26119182). CD21 binds complement fragments C3d, C3dg and iC3b and acts as a receptor for the Epstein-Barr virus (PMID: 7753047). On B cells, together with CD19 and CD81, CD21 forms a complex that functions as a co-receptor to the BCR (PMID: 7542009). It is involved in B cells activation and functions.
实验方案
| Product Specific Protocols | |
|---|---|
| FC protocol for CD21 antibody 65198-1-Ig | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
